ARRIVENT BIOPHARMA INC
AVBP · NASDAQ
Updated at 2026-10-15 06:44:56
- Today's High
- $16.61
- Today’s Low
- $15.26
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $16.06
- Previous Close
- $16.20
- Volume
- 1.58M
- Market Cap
- $798.78M
- P/E Ratio
- --
- EPS
- $-3.67
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 18 CAMPUS BOULEVARD, NEWTOWN SQUARE, PA, UNITED STATES, 19073
- Country
- US
- Listing Date
- 2024-01-26
- Fiscal Year End
- September
- Shares Outstanding
- 46.57M
- CIK
- 0001868279
- Website
- arrivent.com
ArriVent BioPharma, Inc. (AVBP) is a dynamic biopharmaceutical company dedicated to developing pioneering therapies that address critical unmet needs in oncology and autoimmune diseases. The company harnesses proprietary technologies and a strong scientific foundation to create a promising pipeline aimed at enhancing patient outcomes. Positioned in high-growth sectors of the biopharma industry, ArriVent presents an appealing investment opportunity for institutional investors looking to engage in impactful healthcare innovations with substantial market potential.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$52.69M
2026-03-31
$46.11M
2025-12-31
$38.82M
2025-09-30
$38.31M
Net Income
2026-06-30
-$49.89M
2026-03-31
-$43.32M
2025-12-31
-$35.54M
2025-09-30
-$34.97M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-1.05
2026-03-31
$-0.96
2025-12-31
$-0.78
2025-09-30
$-0.83
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$49.89M
2026-03-31
-$43.32M
2025-12-31
-$35.54M
2025-09-30
-$34.97M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $52.69M | $46.11M | $38.82M | $38.31M |
| Net Income | -$49.89M | -$43.32M | -$35.54M | -$34.97M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-1.05 | $-0.96 | $-0.78 | $-0.83 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$49.89M | -$43.32M | -$35.54M | -$34.97M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.